UBS AG reaffirmed their neutral rating on shares of Biogen Inc. (NASDAQ:BIIB) in a research report sent to investors on Wednesday morning, www.benzinga.com reports. UBS AG currently has a $285.00 price objective on the biotechnology company’s stock, up from their prior price objective of $270.00.

A number of other brokerages have also weighed in on BIIB. ValuEngine raised Biogen from a hold rating to a buy rating in a report on Thursday, June 22nd. Mizuho cut their price objective on Biogen from $290.00 to $274.00 and set a neutral rating on the stock in a report on Wednesday, May 31st. Vetr lowered Biogen from a strong-buy rating to a buy rating and set a $310.46 price objective on the stock. in a report on Tuesday, April 25th. Cowen and Company reissued an outperform rating and issued a $271.00 price objective on shares of Biogen in a report on Monday, July 3rd. Finally, William Blair reissued an outperform rating on shares of Biogen in a report on Monday, June 26th. Fourteen research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Biogen currently has an average rating of Buy and a consensus target price of $328.89.

Shares of Biogen (NASDAQ:BIIB) traded down 0.18% on Wednesday, reaching $287.44. The company’s stock had a trading volume of 869,157 shares. The firm has a 50 day moving average price of $274.41 and a 200-day moving average price of $273.68. Biogen has a 12-month low of $244.28 and a 12-month high of $333.65. The stock has a market cap of $60.77 billion, a PE ratio of 18.86 and a beta of 0.78.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, beating analysts’ consensus estimates of $4.36 by $0.68. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The company’s revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the company earned $5.21 earnings per share. Equities research analysts expect that Biogen will post $21.33 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Biogen Inc. (BIIB) Earns “Neutral” Rating from UBS AG” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/biogen-inc-biib-earns-neutral-rating-from-ubs-ag/1462659.html.

In related news, EVP Susan H. Alexander sold 4,974 shares of Biogen stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the transaction, the executive vice president now owns 22,258 shares in the company, valued at $6,455,042.58. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michel Vounatsos acquired 1,402 shares of Biogen stock in a transaction that occurred on Monday, May 1st. The shares were bought at an average price of $271.35 per share, for a total transaction of $380,432.70. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 13,816 shares of company stock worth $3,931,380. 0.32% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in BIIB. Dillon & Associates Inc. increased its position in shares of Biogen by 0.3% in the first quarter. Dillon & Associates Inc. now owns 1,785 shares of the biotechnology company’s stock worth $487,000 after buying an additional 5 shares during the last quarter. Beacon Trust Co. increased its position in shares of Biogen by 0.5% in the first quarter. Beacon Trust Co. now owns 1,135 shares of the biotechnology company’s stock worth $328,000 after buying an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America increased its position in shares of Biogen by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock worth $229,000 after buying an additional 6 shares during the last quarter. Carroll Financial Associates Inc. increased its position in shares of Biogen by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after buying an additional 6 shares during the last quarter. Finally, Trust Co. of Vermont increased its position in shares of Biogen by 0.3% in the first quarter. Trust Co. of Vermont now owns 2,412 shares of the biotechnology company’s stock worth $660,000 after buying an additional 7 shares during the last quarter. Hedge funds and other institutional investors own 87.50% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Analyst Recommendations for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.